Lantern Pharma Q2 net loss $7.1M; LP-300 PFS benefit deepens; OMAI spin-off

Lantern Pharma Inc.

2026-Q2 EPS reported -$0.88

Q2 2026 net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY; operating loss down 25% to $3.5M.
Cash $7.4M at June 30, 2026; raised $4.4M gross from May 14 registered direct offering.
LP-300 HARMONIC: median PFS 8.9 mo in L858R patients completing 6 cycles (n=9) vs 8.4 mo overall (n=16); HR 0.37; FDA cleared protocol amendments to focus on L858R and extend to 8 cycles.
EMA cleared LP-184 Phase 1b/2 bladder cancer trial at Rigshospitalet, Denmark; FDA cleared TNBC trial; USPTO Notice of Allowance for three-gene signature.
Open Medicine AI established as separate company with executed commercial licenses; plans to raise capital at OMAI level.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.